Where is Halozyme located?

Halozyme is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Halozyme have?

As of Aug 31, 2026, the latest employee count at Halozyme is 541.

Is Halozyme a funded company?

Halozyme is a funded company, having raised an undisclosed amount across 10 funding rounds to date. The company's 1st funding round was a $***** Post IPO round.

When was the latest funding round of Halozyme?

Halozyme's latest funding was a $***** Post IPO round on Aug 15, 2022, with participation from 0 investor.

What is the annual revenue of Halozyme?

Annual revenue of Halozyme is more than $1B as on Dec 31, 2025

Where does Halozyme rank among its competitors?

Halozyme ranks 33rd amongst 3533 active competitors, of which 1185 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Halozyme?

Halozyme's top competitors include Jazz Pharmaceuticals, BeiGene and argenx. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Halozyme - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of drug delivery technologies for the treatment of various diseases. The company's lead product is ENHANZE drug delivery technology, based on the proprietary enzyme rHuPH20, which is used to facilitate the delivery of injected drugs and fluids. Also, it offers Hylenex recombinant an endoglycosidase indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.

Website: halozyme.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

1999

Location

San Diego, United States

Stage

Public

Latest Funding Round

Post IPO, Aug 15, 2022, $*****

Investors

Colt Ventures & 9 more

Ranked

33^rd among 3533 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

541 as on Aug 31, 2026

Investment & Acquisitions

Surf Bio & 2 more

Similar Companies

Jazz Pharmaceuticals & 3275 more

Exit Details

Public

View Halozyme's full profile

Halozyme is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
HALOZYME THERAPEUTICS INC CIN: 1159036 , United States, Active	Aug 22, 2007	$1B+ (As on Dec 31, 2025)	373 (As on Feb 29, 2024)	-
HALOZYME THERAPEUTICS, INC CIN: 88-0488686 , United States, Active	Dec 31, 1998	-	145 (As on Dec 31, 2021)	-
Halozyme, Inc. CIN: 330802801 , United States, Active	Dec 26, 999	-	353 (As on Dec 31, 2024)	-

Halozyme got listed on Mar 12, 2004.

Click here to take a look at Halozyme's IPO in detail

Halozyme has raised funding over 10 rounds. Halozyme has 10 institutional investors.

Here is the list of recent funding rounds of Halozyme:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 15, 2022	7336571	Post IPO	3273514	7535574	6971173	6770369
Nov 12, 2019	9927678	Post IPO	6092613	4706765	1038014	7983296
Jan 26, 2016	6792664	Venture Debt	9392637	4282887	8815443	Athyrium Capital Management & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Halozyme's funding rounds and investors

Halozyme's employee count trend

Halozyme has 541 employees as of Aug 26. Here is Halozyme's employee count trend over the years:

Uncover Halozyme's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Halozyme include Jazz Pharmaceuticals, BeiGene and argenx. Here is the list of Top 10 competitors of Halozyme, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
33rd	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, BB Biotech & 8 others	67/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Halozyme's competitors? Click here to see the top ones

Halozyme has acquired 3 companies including Surf Bio, Elektrofi and Antares Pharma. Halozyme has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 28, 2026	Acquisition	Surf Bio	2021	Palo Alto (United States)
Oct 01, 2025	Acquisition	Elektrofi	2016	Boston (United States)
Apr 13, 2022	Acquisition	Antares Pharma	2000	Ewing (United States)